Design, synthesis and insight into the structure-activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 21, 2011, Pages 6297-6300

  An, Hongchan ^a   Kim, Nam Jung ^a   Jung, Jong Wha ^a   Jang, Hannah ^a   Park, Jong Wan ^a   Suh, Young Ger ^a  

^a Seoul National University   (South Korea)

Author keywords

Anti cancer agent; HIF 1 ; Hypoxia; SAR (structure activity relationship); YC 1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1 INHIBITOR; INDAZOLE DERIVATIVE; LIFICIGUAT; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACETYLATION; AMIDATION; ARTICLE; BIOTRANSFORMATION; CATALYSIS; COMPETITIVE INHIBITION; DRUG DESIGN; DRUG SYNTHESIS; ESTERIFICATION; OXIDATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTITUTION REACTION; SUZUKI REACTION;

EID: 80054782808     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.08.120     Document Type: Article

References (20)

1. Semenza, G. L. Oncogene 2010, 29, 625.
2. Zhong, H.; Marzo, A. M. D.; Laughner, E.; Lim, M.; Hilton, D. A.; Zagzag, D.; Buechler, P.; Isaacs, W. B.; Semenza, G. L.; Simons, J. W. Cancer Res. 1999, 59, 5830.
3. Semenza, G. L. Nat. Rev. Cancer 2003, 3, 721.
4. Miyata, T.; Takizawa, S.; de Strihou, C. Am. J. Physiol. Cell. Physiol. 2011, 300, C226.
5. Manolescu, B.; Oprea, E.; Busu, C.; Cercasov, C. Biochimie 2009, 91, 1347.
6. Yeo, E.-J.; Chun, Y.-S.; Cho, Y.-S.; Kim, J.; Lee, J.-C.; Kim, M.-S.; Park, J.-W. J. Natl. Cancer. Inst. 2003, 95, 516.
7. Kim, H.-L.; Yeo, E.-J.; Chun, Y.-S.; Park, J.-W. Int. J. Oncol. 2006, 29, 255.
8. Ko, F.-N.; Wu, C.-C.; Kuo, S.-C.; Lee, F.-Y.; Teng, C.-M. Blood 1994, 84, 4226.
9. Becker, E. M.; Alonso-Alija, C.; Apeler, H.; Gerzer, R.; Minuth, T.; Pleib, U.; Schmidt, P.; Schramm, M.; Schröder, H.; Schroeder, W.; Steinke, W.; Straub, A.; Stasch, J.-P. B. M. C. Pharmacology 2001, 1, 13.
10. Lin, Y.-C.; Chou, L.-C.; Chen, S.-C.; Kuo, S.-C.; Huang, L.-J.; Gean, P.-W. Bioorg. Med. Chem. Lett. 2009, 19, 3225.
11. Chen, C. Y.-C. J. Taiwan Inst. Chem. Eng. 2009, 40, 55.
12. Shin, D. H.; Kim, J.-H.; Jung, Y.-J.; Kim, K.-E.; Jeong, J. M.; Chun, Y.-S.; Park, J.-W. Cancer Lett. 2007, 255, 107.
13. Pan, S.-L.; Guh, J.-H.; Peng, C.-Y.; Wang, S.-W.; Chang, Y.-L.; Cheng, F.-C.; Chang, J.-H.; Kuo, S.-C.; Lee, F.-Y.; Teng, C.-M. J. Pharmacol. Exp. Ther. 2005, 314, 35.
14. Chen, C.-J.; Hsu, M.-H.; Huang, L.-J.; Yamori, -T.; Chung, J.-G.; Lee, F.-Y.; Teng, C.-M.; Kuo, S.-C. Biochem. Pharmacol. 2008, 75, 360.
15. Sun, H.-L.; Liu, Y.-N.; Huang, Y.-T.; Pan, S.-L.; Huang, D.-Y.; Guh, J.-H.; Lee, F.-Y.; Kuo, S.-C.; Teng, C.-M. Oncogene 2007, 26, 3941.
16. Li, S. H.; Shin, D. H.; Chun, Y.-S.; Lee, M. K.; Kim, M.-S.; Park, J.-W. Mol. Cancer. Ther. 2008, 7, 3729.
17. Park, J.-W.; Chun, Y.-S.; Bair, K.; Cho, H. S. WO/2005/030121, 2005.
18. Park, J.-W. WO/2007/065010, 2007.
19. Meanwell, N. A. J. Med. Chem. 2011, 54, 2529.
20. 50 of more than 20 μM and have unexpected cell toxicities at higher concentration.